December 24, 2025 10:58 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Delhi erupts over lynching of Hindu man in Bangladesh; protest outside High Commission | Targeted killing sparks global outrage: American lawmakers condemn mob lynching of Hindu man in Bangladesh | Assam on a ‘powder keg’: Himanta Biswa Sarma flags demographic shift, Chicken’s Neck fears | Bangladesh on edge: Student leader shot as pre-poll violence deepens after Hadi killing | Historic deal sealed: India, New Zealand sign landmark Free Trade Agreement in record time | Supreme court snubs urgent plea to stop PMO’s chadar offering at Ajmer Sharif | Emergency landing drama: Air India flight heads back to Delhi after engine malfunction! | PM Modi slams ‘cut and commission’ TMC in virtual Taherpur address | US launches Operation Hawkeye Strike in Syria targeting ISIS after Americans killed | Horror on tracks: Rajdhani Express ploughs into elephant herd, eight killed in Assam
Johnson&Johnson Vaccine

Kolkata's Peerless Hospital commences Johnson & Johnson vaccine's clinical trial

| @indiablooms | May 08, 2021, at 03:50 am

Kolkata/IBNS: Kolkata's Peerless Hospital has been selected as the only trial venue in the East for Johnson & Johnson for their single-dose vaccine which is currently being used under emergency authorization.

In a statement Dr Subhrajyoti Bhowmick, Clinical trial specialist and clinical Pharmacologist and Director, Clinical Research Peerless Hospital, Kolkata said, " We shall be recruiting 100 participants at this site, six such sites have been selected for this trial of this unique single dose vaccine."

"I am confident we shall get enough volunteers for the clinical trial as vaccine supply is short and the supply of Covishield and Covaxine is less than the huge demand. The ratio shall be 3:1 as three volunteers will get a vaccine while one person shall get a placebo. We are now awaiting the ethics committee approval on which we shall embark on the clinical trials," concluded Bhowmick.

Earlier, Sputnik V, developed by Gamaleya Research Institute of Epidemiology and Microbiology in Russia, has been approved for use in India.

Five million doses of Sputnik V are expected to arrive in India by June.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.